Results of a clinical trial of Cologuard show unprecedented rates of precancer and cancer detection by a noninvasive test.
The detection rates are similar to those reported for colonoscopy. The results were published in the March 20 issue of the New England Journal of Medicine (NEJM). Cologuard was co-developed by Mayo Clinic and Exact Sciences. Cologuard, is a noninvasive sDNA test for the early detection of colorectal precancer and cancer. The Cologuard test is based on a stool sample that is analyzed for DNA signatures of precancer or cancer. The samples are easily collected, mailed from home, requires no bowel preparation, medication restriction or diet change. The clinical trial, called the DeeP-C study, included 10,000 patients and was designed to determine how well Cologuard detects precancer and cancer.
The study also compared Cologuard to the fecal immunochemical test for occult blood (FIT). The study was conducted at 90 medical centers throughout the United States and Canada. “Cologuard detection rates of early stage cancer and high-risk precancerous polyps validated in this large study were outstanding and have not been achieved by other noninvasive approaches,” says the study’s author David Ahlquist M.D., a Mayo Clinic gastroenterologist and co-inventor of the Cologuard test. “It is our hope that this accurate and user-friendly test will expand screening effectiveness and help curb colorectal cancer rates in much the same way as regular Pap smear screening has done for cervical cancer.” In the study, all patients received Cologuard, FIT and colonoscopy. Colonoscopy was the reference method. Major findings reported in the study include:
- Sensitivity of Cologuard for cancer was 92 percent overall, and 94 percent for the earliest and most curable cancer stages (stages I and II).
- Sensitivity was 69 percent for precancerous polyps at greatest risk to progress to cancer (i.e., those containing high-grade dysplasia).
- Cologuard detected significantly more cancers and significantly more precancerous polyps than did FIT.
“The most important finding of the study is the high sensitivity of Cologuard for curable stage colorectal cancer, which represents the highest sensitivity of any noninvasive test to date,” says Thomas Imperiale, M.D., a Professor of Medicine at Indiana University Medical Center in Indianapolis and a study author. “It is also significant to note that these results were achieved in a robustly conducted multicenter study.”
Colorectal cancer is often considered the most preventable, yet least prevented, cancer. Nearly 50 percent of adults age 50 and older have not been screened as recommended and, as a result, colorectal cancer has become the second-leading cause of cancer death in the United States. Colorectal cancer is highly treatable if found early, and it is preventable if the precancerous polyps at greatest risk of progressing can be detected. “Dr. Ahlquist’s work exemplifies our goal at Mayo Clinic, which is the relentless pursuit of innovation aimed to help our patients. This research will transform how we think about colorectal cancer screening going forward,” says Vijay Shah, M.D., chair of Mayo Clinic’s Division of Gastroenterology and Hepatology. Cologuard works by testing a patient’s stool for altered DNA shed during digestion. Altered DNA is known to occur within colorectal cancers and precancerous polyps.
The test also examines the stool for the presence of blood, another possible indicator of colorectal cancer. Combining the data from the stool DNA test and the blood test into a single result provides a comprehensive, powerful screening approach, which is reflected in the study results. Because of its accessibility and ease of use, researchers hope the test will increase the number of people who will choose to be screened for colorectal cancer. Screening is important because, if cancer is detected early, removing polyps during a colonoscopy can prevent the cancer. “This test has the potential to bring colon cancer screening to many patients who might otherwise go without any screening,” says Kenneth Wang, M.D., a Mayo Clinic gastroenterologist, director of the Advanced Endoscopy Group and president of the American Society for Gastrointestinal Endoscopy. “I’m hopeful that this will increase the number of patients obtaining lifesaving colonoscopy with early detection and removal of precancerous and early cancerous polyps.”
The Latest on: Colorectal Cancer Screening
[google_news title=”” keyword=”Colorectal Cancer Screening” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Colorectal Cancer Screening
- Non Invasive Colon Cancer Screening Market Size 2023 Global Industry Development Analysis by Manufacturers Profiles and Forecast till 2026on March 23, 2023 at 11:25 am
Report 2023 "Non Invasive Colon Cancer Screening Market" provides a thorough examination of the present and projected situation of the sector. The research offers useful information about, among other ...
- Intermountain Health tours with giant inflatable colon to raise colon cancer awarenesson March 23, 2023 at 10:06 am
He said it is important for people to know that the only way to detect colon cancer is through a colonoscopy, and that the age of screening used to be 50 but has been lowered to 45. “Many of the risk ...
- March is Colorectal Cancer Awareness Monthon March 23, 2023 at 7:41 am
Melissa Cummings, Chief Customer Officer at Blue Cross & Blue Shield of Rhode Island (BCBSRI), explains the importance of colorectal cancer screening as well as the different options available, ...
- Screening crucial as colorectal cancer in adults under 55 continues to riseon March 22, 2023 at 7:21 pm
March is Colorectal Cancer Awareness Month, and doctors say screenings are critical. Cases in adults under 55 are going up. A new Optum KC Wellness on Wheels mobile unit is making screening easy. "It ...
- 'It doesn't have to be that way.' Doctors urge early screenings for colon canceron March 22, 2023 at 5:46 pm
Vincent Tosti was diagnosed with stage 3 colorectal cancer in 2019. His doctor said his tumor was the size of an apple. It was detected when Tosti was 49 with no family history of colon cancer. The ...
- Lee Health: March is Colorectal Cancer Awareness Monthon March 22, 2023 at 2:12 am
When looking at statistics for women and men combined, colorectal cancer is the second-leading cause of death in Florida ...
- Colon Cancer Is Rising Among Younger Adults. Here’s What to Know.on March 20, 2023 at 2:54 pm
In a study published by the American Cancer Society in March, researchers estimated that in 2023, 153,000 people in the United States would be diagnosed with colorectal cancer. Of those cases, about ...
- March Is Colorectal Cancer Awareness Month- Here’s What You Should Knowon March 20, 2023 at 1:49 pm
Aside from occasionally feeling tired, Robert had no symptoms of colon cancer. Screening tests subsequently showed a positive diagnosis of colon cancer for Robert at the age of 51. He then ...
- With colon cancer on the rise under age 55, doctors work to boost screeningon March 20, 2023 at 12:32 pm
Doctors noted the trend, and now statistics show colon cancer among those under age 55 has doubled since 1995. So they are working to make patients aware and get them in for the first screening.
- LCMC uses early and detailed screening to address colorectal cancer among patientson March 18, 2023 at 10:00 pm
Colon cancer screenings are now recommended for people beginning in their 40s. LCMC Health in New Orleans has advanced technology to detect cancer sooner.
via Bing News